The FDA cleared Viridian Therapeutics’ IGF-1R antagonist Lumvoa (veligrotug-vvze) for thyroid eye disease, including both active and chronic phases, setting up immediate competition with Amgen’s Tepezza. Viridian said the drug’s label carries broadly similar safety language to Tepezza. Wall Street analysis cited Lumvoa’s statistically significant effect in diplopia response and complete resolution outcomes across forms of TED. Viridian also launched a patient-support program designed to improve access at launch. For TED-focused developers and payers, the clearance increases the number of approved options and raises expectations that payer dynamics and utilization management will tighten as new pricing and coverage positions emerge.